Compare Novartis AG (NVS) vs Unilever plc (UL) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Unilever (UL) trades at $63.54, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings misses contrast with strong profitability, including a net income margin of 18.32% and ROE of 54.57% for 2025. The company reported its strongest quarterly volume growth in over a decade in Q2 2026, raising its full-year outlook, while strategic shifts include focusing on beauty and personal care and a planned $65 billion merger with McCormick.

The outlook is mixed: robust fundamentals and strategic refocusing support long-term growth, particularly in emerging markets, but consistent earnings misses and a high P/E ratio of 21.46 pose valuation concerns. Risks include integration challenges from the McCormick deal and competitive pressures. Analyst consensus is divided, with 24% buy ratings, highlighting cautious optimism amid execution uncertainties.